FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286293732> ?p ?o ?g. }

• W4286293732 endingPage "e15093" @default.
• W4286293732 startingPage "e15093" @default.
• W4286293732 abstract "e15093 Background: Phosphoinositide 3-kinase (PI3K) is an attractive anti-cancer drug target due to its promotion of cell growth and proliferation; however, available pan-PI3K inhibitors currently lack specificity, leading to excessive drug toxicity and adverse effects. Selectide-18 is a novel PI3K inhibitor that targets PI3K’s catalytic subunit p110β, resulting in reduced viability of cancer cells. The p110β subunit is the most prominent PI3K subunit in many chemoresistant tumors. Previous research has revealed a unique 18-residue long motif within the C2 domain of p110β. This motif is not found in other catalytic subunits (p110α, p110δ, or p110γ), making it a promising drug target. Selectide-18 is a memetic peptide drug modeled after this motif and has been shown to effectively inhibit p110β binding without affecting other isoforms, separating it from currently available pan-PI3K inhibitors. While Selectide-18 has been successful in inhibiting PI3K in previous studies, it has poor cell permeability due to its large size. Previous findings have revealed functional redundancies among Selectide-18’s residues. This study aims to remove these redundancies and determine the optimal formulation of Selectide-18 through in silico analysis. Methods: An in silico protocol was developed to determine the optimal formulation of Selectide-18. By utilizing the PEP-FOLD server, 455 peptide models were created using 91 unique fragments of the Selectide-18 amino acid sequence ranging in size from 6 to 17 residues. Physical conformation of each model was compared to wild-type Selectide-18 using root-mean-square deviation data collected using PyMOL and UCSF Chimera software. Computational docking through AutoDock Vina was performed to test the binding affinity of each model to the active site of regulatory subunit p85α. The distance between each drug and the active site was measured with UCSF Chimera’s distance function. Finally, ClusPro docking of drug-bound p85α/p110β was compared to wild-type p85α/p110β, as well as non-truncated Selectide-18-bound p85α/p110β. Statistical significance was determined using a Student's t-test. Results: Select truncated models demonstrated physical confirmation (RMSD = 0.024), binding affinity (-8.74 kcal/mol), and simulated inhibitory capabilities comparable to Selectide-18. A specific group of variants comprised of 9 amino acids (9 residue_6K-14Q) had the shortest formulation without significant declines in binding affinity. Conclusions: Selectide-18 is a selective PI3K inhibitor that can be optimized by removing functionally redundant amino acids. A 9-residue variant ranging from amino acids 6 Lys to 14 Gln showed the most promise and will be used in future studies to reformulate Selectide-18. Being half the size of Selectide-18, this optimized drug is anticipated to have improved cell permeability without sacrificing inhibitory function." @default.
• W4286293732 created "2022-07-21" @default.
• W4286293732 creator A5027172046 @default.
• W4286293732 creator A5039901468 @default.
• W4286293732 creator A5040428803 @default.
• W4286293732 creator A5052193554 @default.
• W4286293732 creator A5066552446 @default.
• W4286293732 date "2022-06-01" @default.
• W4286293732 modified "2023-09-24" @default.
• W4286293732 title "Precision medicine: Novel PI3K inhibitor as cancer treatment." @default.
• W4286293732 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e15093" @default.
• W4286293732 hasPublicationYear "2022" @default.
• W4286293732 type Work @default.
• W4286293732 citedByCount "0" @default.
• W4286293732 crossrefType "journal-article" @default.
• W4286293732 hasAuthorship W4286293732A5027172046 @default.
• W4286293732 hasAuthorship W4286293732A5039901468 @default.
• W4286293732 hasAuthorship W4286293732A5040428803 @default.
• W4286293732 hasAuthorship W4286293732A5052193554 @default.
• W4286293732 hasAuthorship W4286293732A5066552446 @default.
• W4286293732 hasConcept C104292427 @default.
• W4286293732 hasConcept C104317684 @default.
• W4286293732 hasConcept C185592680 @default.
• W4286293732 hasConcept C2775905019 @default.
• W4286293732 hasConcept C2781465904 @default.
• W4286293732 hasConcept C502942594 @default.
• W4286293732 hasConcept C55493867 @default.
• W4286293732 hasConcept C62478195 @default.
• W4286293732 hasConcept C70721500 @default.
• W4286293732 hasConcept C71924100 @default.
• W4286293732 hasConcept C86554907 @default.
• W4286293732 hasConcept C86803240 @default.
• W4286293732 hasConceptScore W4286293732C104292427 @default.
• W4286293732 hasConceptScore W4286293732C104317684 @default.
• W4286293732 hasConceptScore W4286293732C185592680 @default.
• W4286293732 hasConceptScore W4286293732C2775905019 @default.
• W4286293732 hasConceptScore W4286293732C2781465904 @default.
• W4286293732 hasConceptScore W4286293732C502942594 @default.
• W4286293732 hasConceptScore W4286293732C55493867 @default.
• W4286293732 hasConceptScore W4286293732C62478195 @default.
• W4286293732 hasConceptScore W4286293732C70721500 @default.
• W4286293732 hasConceptScore W4286293732C71924100 @default.
• W4286293732 hasConceptScore W4286293732C86554907 @default.
• W4286293732 hasConceptScore W4286293732C86803240 @default.
• W4286293732 hasIssue "16_suppl" @default.
• W4286293732 hasLocation W42862937321 @default.
• W4286293732 hasOpenAccess W4286293732 @default.
• W4286293732 hasPrimaryLocation W42862937321 @default.
• W4286293732 hasRelatedWork W2045827067 @default.
• W4286293732 hasRelatedWork W2106436765 @default.
• W4286293732 hasRelatedWork W2120091640 @default.
• W4286293732 hasRelatedWork W2367511620 @default.
• W4286293732 hasRelatedWork W2398689959 @default.
• W4286293732 hasRelatedWork W2412777305 @default.
• W4286293732 hasRelatedWork W2895656753 @default.
• W4286293732 hasRelatedWork W2966896562 @default.
• W4286293732 hasRelatedWork W2970101604 @default.
• W4286293732 hasRelatedWork W3158376581 @default.
• W4286293732 hasVolume "40" @default.
• W4286293732 isParatext "false" @default.
• W4286293732 isRetracted "false" @default.
• W4286293732 workType "article" @default.